AVDL Insider Trading

Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $526,363.04
Insider Selling (Last 12 Months): $0.00

Avadel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Avadel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$120kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Avadel Pharmaceuticals Share Price & Price History

Current Price: $8.53
Price Change: Price Decrease of -0.04 (-0.47%)
As of 03/24/2025 05:00 PM ET

This chart shows the closing price history over time for AVDL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$8.57Closing price on 03/23/25:

SEC Filings (Institutional Ownership Changes) for Avadel Pharmaceuticals (NASDAQ:AVDL)

69.19% of Avadel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVDL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$90Mbought$48MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Avadel Pharmaceuticals logo
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More on Avadel Pharmaceuticals

Today's Range

Now: $8.53
Low: $8.42
High: $8.68

50 Day Range

MA: $8.15
Low: $7.49
High: $9.09

52 Week Range

Now: $8.53
Low: $7.39
High: $19.09

Volume

658,405 shs

Average Volume

1,184,163 shs

Market Capitalization

$824.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Who are the company insiders with the largest holdings of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' top insider investors include:
  1. Gregory J Divis (CEO)
  2. Peter J Thornton (Director)
  3. Thomas S Mchugh (CFO)
  4. Geoffrey Michael Glass (Director)
  5. Linda Palczuk (Director)
  6. Mark Anthony Mccamish (Director)
Learn More about top insider investors at Avadel Pharmaceuticals.

Who are the major institutional investors of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' top institutional investors include:
  1. Janus Henderson Group PLC — 14.61%
  2. Polar Capital Holdings Plc — 4.58%
  3. Two Seas Capital LP — 4.46%
  4. Two Seas Capital LP — 4.46%
  5. Braidwell LP — 4.26%
  6. Vanguard Group Inc. — 4.10%
Learn More about top institutional investors of Avadel Pharmaceuticals stock.

Which major investors are selling Avadel Pharmaceuticals stock?

Within the last quarter, AVDL stock was sold by these institutional investors:
  1. Vestal Point Capital LP
  2. Woodline Partners LP
  3. Polar Capital Holdings Plc
  4. Bank of America Corp DE
  5. New York State Common Retirement Fund
  6. Nomura Holdings Inc.
  7. Group One Trading LLC
  8. Barclays PLC

Which major investors are buying Avadel Pharmaceuticals stock?

During the last quarter, AVDL stock was acquired by institutional investors including:
  1. Two Seas Capital LP
  2. Two Seas Capital LP
  3. Brandes Investment Partners LP
  4. Janus Henderson Group PLC
  5. Braidwell LP
  6. Kennedy Capital Management LLC
  7. Renaissance Technologies LLC
  8. Knott David M Jr
Within the last year, these company insiders have bought Avadel Pharmaceuticals stock:
  1. Gregory J Divis (CEO)
  2. Peter J Thornton (Director)
  3. Thomas S Mchugh (CFO)
  4. Geoffrey Michael Glass (Director)
  5. Linda Palczuk (Director)
Learn More investors buying Avadel Pharmaceuticals stock.